New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer

Author(s): Rita Assi, Sally Temraz, Ali Shamseddine, Deborah Mukherji

Journal Name: Current Drug Targets

Volume 17 , Issue 3 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


The androgen receptor (AR) signalling pathway remains a key driver of prostate cancer progression despite castrate levels of testosterone in advanced disease. The androgen biosynthesis inhibitor abiraterone and the anti-androgen enzalutamide have been shown to prolong survival in randomized clinical trials both pre-and post-docetaxel chemotherapy and are now in routine clinical use. With the use of these drugs and other novel survival-prolonging therapeutics, patients with advanced prostate cancer are now living longer with better quality of life. This article will review pre-clinical and clinical data for AR-targeting therapeutics for advanced prostate cancer with a focus on mechanisms of resistance and future directions for research.

Keywords: Prostate cancer, androgen receptor, abiraterone, enzalutamide.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 25 January, 2016
Page: [290 - 302]
Pages: 13
DOI: 10.2174/1389450116666150907101044
Price: $65

Article Metrics

PDF: 54